GHRP-2 5 MG

Dragon Pharma GHRP-2

GHRP-2 5 mg delivers a research-grade dose of Pralmorelin, a potent synthetic hexapeptide and second-generation Growth Hormone Releasing Peptide. As a structural analog of the natural hormone ghrelin, GHRP-2 exerts its effects through selective agonism of the growth hormone secretagogue receptor (GHS-R), triggering a powerful release of growth hormone (GH) from the anterior pituitary gland. What distinguishes GHRP-2 in research is its unique dual-action mechanism: it not only directly stimulates GH secretion but also suppresses somatostatin—the primary hormone that inhibits GH release—creating a synergistic amplification of the GH pulse. This makes GHRP-2 one of the most potent GH secretagogues available for research, with studies showing it can increase GH levels by 7 to 15-fold above baseline.

For bodybuilders, athletes, and anti-aging researchers in the USA, Dragon Pharma GHRP-2 5 mg represents a powerful tool for studying body composition optimization and recovery enhancement. Research focuses on its potential to promote lean muscle mass accretion through increased protein synthesis, enhance fat metabolism via lipolysis, improve connective tissue strength and repair, and potentially increase bone density. Unlike GHRP-6, GHRP-2 exhibits minimal effects on cortisol and prolactin secretion in research models, offering a "cleaner" GH stimulation profile that's particularly valuable for studies where hormonal balance is a key variable. Manufactured by Dragon Pharma under strict quality control in certified European laboratories, this 5 mg vial of lyophilized powder provides researchers with a consistent, high-purity compound for investigating the multifaceted benefits of amplified GH secretion.

Key Benefits:

• Potent GH Stimulation: Triggers 7-15 fold increases in growth hormone levels through dual-action (direct stimulation + somatostatin suppression).
• Selective Receptor Action: Highly selective for GH release with minimal effects on cortisol and prolactin compared to other GHRPs.
• Enhanced Body Composition Effects: Research focuses on increased protein synthesis, accelerated fat metabolism, and improved connective tissue repair.
• Minimal Hunger Stimulation: Unlike GHRP-6, causes significantly less ghrelin-mediated appetite increase, beneficial for cutting phase research.
• Optimal Research Concentration: 5 mg per vial provides ideal material for daily or multiple-daily administration protocols in extended studies.

Each 2 mL vial contains 5 mg of high-purity GHRP-2 peptide (Pralmorelin) as a sterile lyophilized powder, synthesized using advanced peptide chemistry under Dragon Pharma's pharmaceutical-grade manufacturing standards.

Product Specifications

Usage Guidelines

Research Application Only: This information summarizes scientific literature for educational context. Dragon Pharma GHRP-2 5 mg is a research chemical for laboratory investigation, not for human consumption.

In experimental settings, GHRP-2 is reconstituted with bacteriostatic water. Research protocols typically utilize subcutaneous administration. To maximize GH pulsatility and mimic natural secretion patterns, studies often split the daily dose into 2-3 administrations (e.g., morning, post-training, before bedtime). Administration on an empty stomach or at least 2 hours post-meal is common to avoid insulin interference. Due to its short half-life, effects are transient but potent, making timing crucial in study designs. Research cycles are typically limited to 8-12 weeks with 4-week breaks to prevent pituitary desensitization. Blood glucose monitoring may be included in protocols, as GH can transiently affect insulin sensitivity.

• Standard Body Composition Research Cycle (8-10 weeks): 2-3 daily administration protocol to study effects on muscle protein synthesis, fat loss, and recovery markers, followed by a 4-week off period.
• Advanced Performance & Recovery Study (12 weeks): Extended cycle focusing on connective tissue repair, injury recovery, and metabolic parameters, often with careful monitoring of fasting glucose.

Post Cycle Therapy (PCT):

As a GH secretagogue, GHRP-2 does not suppress the HPTA, so traditional PCT with SERMs like Clomid is not applicable. The primary research consideration is pituitary receptor sensitivity recovery. A 4-week minimum break between cycles is standard. Some protocols incorporate a switch to a GHRH like Sermorelin during the off-period for gentle stimulation. For comprehensive recovery research post-cycle, compounds like BPC-157 could be studied for tissue repair maintenance.

Synergistic Research Combinations:

GHRP-2 is often studied in combination with other peptides for enhanced effects. For maximal GH stimulation research, it pairs powerfully with CJC-1295 DAC (long-acting GHRH) or CJC No DAC/Ipamorelin blends. For body recomposition studies, combining with Tesamorelin (for visceral fat reduction) could be explored. In athletic performance research, pairing with IGF-1 LR3 may study muscle growth synergy. For cutting phase studies, combining with Mazdutide could examine appetite and metabolic effects.

Third-Party Lab Tested

2025-11-07

View Result

5.88 mg

Lab Analysis Note: The November 2025 third-party HPLC test confirms 5.88 mg of GHRP-2 peptide per vial—117.6% of the labeled 5 mg. This significant overfill demonstrates Dragon Pharma's commitment to premium research products. Mass spectrometry verifies the correct hexapeptide sequence (D-Ala-D-βNal-Ala-Trp-D-Phe-Lys-NH₂) with ≥98% purity, ensuring researchers receive a potent, accurately dosed compound for GH secretion studies.

Storage Instructions

Proper storage is essential to maintain the stability and potency of this research peptide.

• Unreconstituted Powder: Store the sealed vial in a freezer at -20°C (-4°F) or colder for long-term stability. In this lyophilized state, GHRP-2 remains stable for up to 24 months. Protect from light and moisture, and avoid repeated freeze-thaw cycles.
• After Reconstitution: Once reconstituted with bacteriostatic water, the solution must be refrigerated immediately at 2°C to 8°C (36°F to 46°F). The reconstituted solution is typically stable for research use for 3-4 weeks when refrigerated. For best results in multi-daily dosing studies, use within 21 days. Never freeze the liquid solution.
• Important for Research Protocols: Given that studies often use 2-3 daily administrations, it's practical to reconstitute only enough for 1-2 weeks of research to ensure maximum peptide integrity throughout the dosing period.